

Figure S3. Effects of the NLRP3 inflammasome on cytokine induction. BMDCs (*n* = 3) from C57BL/6 or *Nlrp3*$^{-/-}$ mice were pretreated with 25 μg/ml of the IFNAR receptor blocking antibody MAR1-5A3 or an isotype control GIR-208 for 30 minutes prior to infection with WNV and at 48 hours cells were collected. **A**. Western blot showing the expression of STAT1, the ISG IFIT2, the WNV protein NS3, and IL-1β cleavage. **B**. Viral titers from the treated BMDCs were determined by a focus-forming assay. Data are shown as FFU per ml. Error bars indicate SD. **C**. Relative cytokine mRNA levels at 48 hours from WT or *Nlrp3*$^{-/-}$ BMDCs infected with WNV after

treatment with MAR1-5A3 or an isotype control MAb. Gene expression was measured by qRT-PCR and normalized to *Gapdh* levels. Data is displayed as the fold increase compared to untreated cells on a log2 scale. Data represent the average of three independent experiments. Error bars indicate SD. The limit of detection was assigned as a value log2 $\Delta\Delta$Ct of -2. **D**. The concentration of IL-1β, IL-6 and TNF-α in serum from the treated WT and *Nlrp3*$^{-/-}$ mice was determined by cytokine bioplex assay. Mean values $\pm$ SD are shown. **E-G**. WT, *Nlrp3*$^{-/-}$, *caspase-1/11*$^{-/-}$ or *IL-1R*$^{-/-}$ mice were pretreated one day prior to WNV infection with 1 mg (40 mg/kg) of the IFNAR receptor blocking antibody MAR1-5A3 or isotype control MAb (GIR-208) prior. At 72 hours after infection, serum was collected and analyzed for ALT (**E**), AST (**F**), and glucose (**G**).